Previous 10 | Next 10 |
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today in conjunction with an announcement to be issued by Legend Biotech...
Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range of $16-$18.Underwriters' over-allotment is an additional 1,474,202 shares. Shares to kick-off trading t...
Jacobio raised $174 million in a Hong Kong IPO to develop its portfolio of 12 novel drugs. WuXi Biologics will add more CDMO capacity by spending $183 million to acquire a Bayer facility in Germany. CASI Pharma announced its partnered CD19 CAR-T product was granted Breakthrough De...
Janssen Pharmaceutical, a unit of Johnson & Johnson ([[JNJ]] -0.9%) has started rolling submission of its marketing application to the FDA seeking approval for ciltacabtagene autoleucel (cilta-cel), for the treatment of adults with relapsed and/or refractory multiple myeloma.Cilta-cel is ...
Legend Biotech also achieves fifth milestone payment under its collaboration agreement with Janssen in clinical development of cilta-cel Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in t...
Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie. Legend Biotech was cleared to start a US Phase I trial...
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate virtually in the 39 th Annual J.P. Morg...
Legend Biotech (LEGN) selected for addition to the NASDAQ Biotechnology Index, effective prior to market open on Monday, December 21, 2020. For this year’s re-ranking of the index, 100 biotech stocks were added and 16 were removed.Shares +1.1% after hours.Press Rele...
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has been selected for addition to th...
The FDA has signed-off Legend Biotech's ([[LEGN]] +11.1%) investigational new drug application to evaluate LB1901, an autologous chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of adults with relapsed or refractory T-cell lymphoma.Upcoming Phase 1 multicohort study will en...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...